NCT04578496View on ClinicalTrials.gov

A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 11, 2011

Primary Completion Date

February 27, 2014

Study Completion Date

February 27, 2014

Conditions
Erythropoietic Protoporphyria
Interventions
DRUG

Afamelanotide

Sponsors
All Listed Sponsors
lead

Clinuvel Pharmaceuticals Limited

INDUSTRY